Finch Therapeutics Group Inc. (NASDAQ: FNCH)
$1.82
+0.2400 ( +15.19% ) 629.5K
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
Market Data
Open
$1.82
Previous close
$1.58
Volume
629.5K
Market cap
$2.89M
Day range
$1.47 - $2.19
52 week range
$0.80 - $9.48
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 10, 2024 |
8-k | 8K-related | 13 | May 24, 2024 |
4 | Insider transactions | 1 | May 24, 2024 |
8-k | 8K-related | 13 | May 17, 2024 |
10-q | Quarterly Reports | 65 | May 10, 2024 |
10-k/a | Quarterly Reports | 13 | Apr 26, 2024 |
8-k | 8K-related | 13 | Apr 03, 2024 |
4 | Insider transactions | 1 | Mar 29, 2024 |
10-k | Annual reports | 89 | Mar 25, 2024 |
8-k | 8K-related | 14 | Feb 23, 2024 |